Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT

Arnon Nagler*, Frédéric Baron, Myriam Labopin, Emmanuel Polge, Jordi Esteve, Ali Bazarbachi, Eolia Brissot, Gesine Bug, Fabio Ciceri, Sebastian Giebel, Maria H. Gilleece, Norbert Claude Gorin, Francesco Lanza, Zinaida Peric, Annalisa Ruggeri, Jaime Sanz, Bipin N. Savani, Christoph Schmid, Roni Shouval, Alexandros SpyridonidisJurjen Versluis, Mohamad Mohty

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Detectable measurable residual disease (MRD) is a key prognostic factor in both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Thus, we conducted a survey in EBMT transplant centers focusing on pre- and post-allo-HCT MRD. One hundred and six centers from 29 countries responded. One hundred had a formal strategy for routine MRD assessment, 91 for both ALL and AML. For ALL (n = 95), assessing MRD has been routine practice starting from 2010 (range, 1990–2019). Techniques used for MRD assessment consisted of PCR techniques alone (n = 27), multiparameter flow cytometry (MFC, n = 16), both techniques (n = 43), next-generation sequencing (NGS) + PCR (n = 2), or PCR + MFC + NGS (n = 7). The majority of centers assessed MRD every 2–3 months for 2 (range, 1-until relapse) years. For AML, assessing MRD was routine in 92 centers starting in 2010 (range 1990–2019). Assessment of MRD was by PCR (n = 23), MFC (n = 13), both PCR and MFC (n = 39), both PCR and NGS (n = 3), and by all three techniques (n = 14). The majority assesses MRD for AML every 2–3 months for 2 (range, 1-until relapse) years. This survey is the first step in the aim to include MRD status as a routine registry capture parameter in acute leukemia.

Original languageEnglish
Pages (from-to)218-224
Number of pages7
JournalBone Marrow Transplantation
Volume56
Issue number1
DOIs
StatePublished - Jan 2021

Funding

FundersFunder number
National Fund for Scientific Research
Fonds De La Recherche Scientifique - FNRS

    Fingerprint

    Dive into the research topics of 'Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT'. Together they form a unique fingerprint.

    Cite this